Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

Stuart Ainsworth; Stefanie Menzies; Richard Pleass

doi:10.12688/wellcomeopenres.15990.1

Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

Stuart Ainsworth
, Stefanie Menzies
, Richard Pleass

Tropical Disease Biology

Research output: Contribution to journal › Article › peer-review

Abstract

Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may

Original language	English
Article number	115
Journal	Wellcome Open Research
Volume	5
DOIs	https://doi.org/10.12688/wellcomeopenres.15990.1
Publication status	Published - 2 Jun 2020

Access to Document

10.12688/wellcomeopenres.15990.1Licence: CC BY

Ainsworth et al 2020 Animal derived antibodies Wellcome Open Res-June-20Final published version, 595 KBLicence: CC BY

Cite this

@article{f138e698837a4737a0257d24ea951894,

title = "Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19",

abstract = "Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may",

author = "Stuart Ainsworth and Stefanie Menzies and Richard Pleass",

year = "2020",

month = jun,

day = "2",

doi = "10.12688/wellcomeopenres.15990.1",

language = "English",

volume = "5",

journal = "Wellcome Open Research",

issn = "2398-502X",

publisher = "F1000 Research Ltd",

}

TY - JOUR

T1 - Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

AU - Ainsworth, Stuart

AU - Menzies, Stefanie

AU - Pleass, Richard

PY - 2020/6/2

Y1 - 2020/6/2

N2 - Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may

AB - Published data on the first 5,000 coronavirus patients to receive plasma shows promise in the United States. However, delivering convalescent plasma therapies in low- and even middle-income countries is both difficult and costly. Here we discuss the advantages and disadvantages of antisera raised in animals that may

U2 - 10.12688/wellcomeopenres.15990.1

DO - 10.12688/wellcomeopenres.15990.1

M3 - Article

SN - 2398-502X

VL - 5

JO - Wellcome Open Research

JF - Wellcome Open Research

M1 - 115

ER -

Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19

Abstract

Access to Document

Fingerprint

Cite this